Adverse events · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Treatment failure · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes treatment failure compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Chronic lung disease · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Duration of any form of respiratory support (any form of non‐invasive respiratory support with or without supplemental oxygen) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
ICU length of stay (general intensive care patients) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Adverse events ‐ nasal trauma · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes adverse events ‐ nasal trauma compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Adverse events ‐ abdominal overdistention · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes adverse events ‐ abdominal overdistention compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Death · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Treatment failure · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
Summary of findings table ‐ High flow nasal cannula (HFNC) may leads to lower treatment failure compared with low flow nasal cannula (LFNC) (low certainty).
1 finding from 1 review
Total mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in all‐cause mortalitya compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Strokea · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in strokea compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Any bleedingb · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in any bleedingb compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Adverse events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thromboembolic events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in any thromboembolic event compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Major bleeding · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in major bleeding compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Frequency of defecation (mean number of bowel movements per week) · patients aged 0 to 18 years with a diagnosis of functional constipation
1 finding from 1 review
Need for extra treatment · patients aged 0 to 18 years with a diagnosis of functional constipation
It is very uncertain whether high dose PEG changes need for additional therapy compared with low dose PEG (very low certainty).
1 finding from 1 review
Faecal incontinence · patients aged 0 to 18 years with a diagnosis of functional constipation
It is very uncertain whether high dose PEG changes faecal incontinence compared with low dose PEG (very low certainty).
1 finding from 1 review
Adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation
It is very uncertain whether high dose PEG changes adverse events compared with low dose PEG (very low certainty).
1 finding from 1 review
Event‐free survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
High‐dose chemotherapy followed by autologous haematopoietic cell… showed no clear difference in event‐free survival (reported as number of participants with… compared with conventional chemotherapy plus whole lung irradiation (low certainty).
1 finding from 1 review